Comparison of 3-month cytogenetic and molecular assays for early assessment of long-term clinical impact after BCR-ABL1 tyrosine kinase inhibitor treatment in chronic myeloid leukemia

Deininger, 2000, The molecular biology of chronic myeloid leukemia, Blood, 96, 3343, 10.1182/blood.V96.10.3343 Hochhaus, 2017, Long-term outcomes of imatinib treatment for chronic myeloid leukemia, N. Engl. J. Med., 376, 917, 10.1056/NEJMoa1609324 Kantarjian, 2021, Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis, Leukemia, 35, 440, 10.1038/s41375-020-01111-2 Cortes, 2016, Final 5-Year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial, J. Clin. Oncol., 34, 2333, 10.1200/JCO.2015.64.8899 Do, 2020, Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE), Br. J. Haematol., 189, 303, 10.1111/bjh.16381 Cortes, 2018, Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial, J. Clin. Oncol., 36, 231, 10.1200/JCO.2017.74.7162 Marin, 2012, Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors, J. Clin. Oncol., 30, 232, 10.1200/JCO.2011.38.6565 Hanfstein, 2012, Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML), Leukemia, 26, 2096, 10.1038/leu.2012.85 Hughes, 2014, Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib, Blood, 123, 1353, 10.1182/blood-2013-06-510396 Branford, 2014, Prognosis for patients with CML and &10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline, Blood, 124, 511, 10.1182/blood-2014-03-566323 Shanmuganathan, 2021, Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia, Blood, 137, 1196, 10.1182/blood.2020005514 Song, 2018, BCR-ABL1 transcript levels at 4 weeks have prognostic significance for time-specific responses and for predicting survival in chronic-phase chronic myeloid leukemia patients treated with various tyrosine kinase inhibitors, Cancer Med., 7, 5107, 10.1002/cam4.1753 Baccarani, 2013, European LeukemiaNet recommendations for the management of chronic myeloid leukemia, Blood, 122, 872, 10.1182/blood-2013-05-501569 Akard, 2014, Correlations between cytogenetic and molecular monitoring among patients with newly diagnosed chronic myeloid leukemia in chronic phase: post hoc analyses of the Rationale and Insight for Gleevec High-Dose Therapy study, Arch. Pathol. Lab. Med., 138, 1186, 10.5858/arpa.2013-0584-OA Ross, 2006, Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL, Leukemia, 20, 664, 10.1038/sj.leu.2404139 Wang, 2002, Serial monitoring of BCR-ABL by peripheral blood real-time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia, Br. J. Haematol., 118, 771, 10.1046/j.1365-2141.2002.03705.x Lauseker, 2014, Equivalence of BCR-ABL transcript levels with complete cytogenetic remission in patients with chronic myeloid leukemia in chronic phase, J Cancer Res Clin, 140, 1965, 10.1007/s00432-014-1746-8 Kantarjian, 2003, Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia, Clin. Cancer Res., 9, 160 Lange, 2004, Quantitative reverse transcription polymerase chain reaction should not replace conventional cytogenetics for monitoring patients with chronic myeloid leukemia during early phase of imatinib therapy, Haematologica, 89, 49 Hochhaus, 2020, Recommendations for treating chronic myeloid leukemia, Leukemia, 34, 966, 10.1038/s41375-020-0776-2 Lee, 2015, Distinct predictive factors influence on achievement of early molecular response by frontline imatinib in chronic phase chronic myeloid leukemia, Leuk. Res., 39, 411, 10.1016/j.leukres.2015.01.011 Lee, 2018, Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib, Leuk. Res., 70, 100, 10.1016/j.leukres.2018.06.002 Jabbour, 2014, Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION), Blood, 123, 494, 10.1182/blood-2013-06-511592 Kwak, 2017, Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia, Clin. Cancer Res., 23, 7180, 10.1158/1078-0432.CCR-17-0957 Mahon, 1998, Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant interferon-alpha, Blood, 92, 4059, 10.1182/blood.V92.11.4059 O’Brien, 2003, Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia, N. Engl. J. Med., 348, 994, 10.1056/NEJMoa022457 Guilhot, 1997, Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group, N. Engl. J. Med., 337, 223, 10.1056/NEJM199707243370402 Merx, 2002, Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha, Leukemia, 16, 1579, 10.1038/sj.leu.2402680 Wang, 2003, The early molecular response to imatinib predicts cytogenetic and clinical outcome in chronic myeloid leukaemia, Br. J. Haematol., 120, 990, 10.1046/j.1365-2141.2003.04200.x Qin, 2017, Concordant optimal molecular and cytogenetic responses at both 3 and 6 months predict a higher probability of MR4.5 achievement in patients with chronic myeloid leukemia treated with imatinib, Leuk. Lymphoma, 58, 1384, 10.1080/10428194.2016.1239260 Stella, 2019, Clinical implications of discordant early molecular responses in CML patients treated with imatinib, Int. J. Mol. Sci., 20, 2226, 10.3390/ijms20092226 Hochhaus, 2016, Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial, Leukemia, 30, 1044, 10.1038/leu.2016.5 Saglio, 2010, Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia, N. Engl. J. Med., 362, 2251, 10.1056/NEJMoa0912614